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Single-dose liposomal 
amphotericin B for 
visceral leishmaniasis
Dinesh Mondal and colleagues (January, 
p e51)1 investigated the safety and 
efficacy of single-dose liposomal 
amphotericin B for treatment of 
visceral leishmaniasis (also known as 
kala azar) in Bangladesh. The successful 
admin istration of single-dose lipo-
somal amphotericin B at a primary 
health centre is heartening. In a linked 
Comment, Prabhat Kumar Sinha and 
Sujit Bhattacharya2 discussed adverse 
events reported in the study. Concerns 
about potential risks of adverse drug 
reactions and resistance prompted 
WHO to initiate pharmacovigilance 
for miltefosine,3 another drug used to 
treat leishmaniasis, and develop an 
educational manual for patients and 
health workers.4 Pharmacovigilance and 
reporting of adverse drug reactions, 
especially at primary health centres, 
remain difficult. Efforts are needed 
for post-marketing surveillance of 
single-dose liposomal amphotericin B 
for cost, beneﬁ t, and safety in real life. 
Sinha and Bhattacharya also refer to 
the high cost of treatment with liposo-
mal amphotericin B (Ambisome, Gilead, 
USA). An alternative low-cost 
formulation, developed in academic 
institutions in India with funding 
from the Indian Department of 
Biotechnology,5 has been tested 
for leishmaniasis6 and has been 
commercialised as Fungisome (Lifecare, 
India) by a scientist entrepreneur, and 
could be provided a much lower price 
than that of Ambisome. Post-marketing 
surveillance has been done with results 
similar to those of pre-marketing 
phase 1–3 studies.7 Clinical trials funded 
by the Indian Government of single 
doses of this formulation are underway, 
and have shown promising initial results 
for safety and eﬃ  cacy. We hope that 
this drug will further lower the cost of 
treatment, making therapy aﬀ ordable 
to patients with the greatest need.
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